Group items tagged

After struggling with COVID, Hemant Petal is back to good health, and now he is on a mission to reduce "health inequalities". Speaking at the SIGMA Conference 2023, he spoke about his new role as Clinical Lead, Health Inequalities and Population Health Management, SE Essex Alliance, Essex ICB. "So, my new role is outside pharmacy, nothing to do with pharmacy. But it is important, I feel that I share some of my insights about the work that I'm doing that might benefit you," he said. Elaborating on the role of integrated care boards (ICBs), he said that they are designed to enhance coordination and collaboration across different healthcare providers and settings. The representatives from hospitals, community services, retail and social care meet on a monthly basis to "look at where there are issues to be resolved, perhaps what can be done to improve the healthcare services."

The Leverhulme Trade Charities Trust (LTCT) has announced the launch of a new scheme to support pharmacists and their families during the back-to-school period. Opening at 9 am on Tuesday, June 18, 2024, the 'School Essentials Grant' is designed to alleviate financial pressure for people working in community pharmacies with young children during one of the most costly times of the year. The scheme will see the charity provide up to £100,000 of support to pharmacists in need of financial aid. Eligible families can apply online to receive £150 per school-age child, up to a maximum of three children per household. This grant can be used for essential expenses such as new school uniforms, stationery, or travel passes. The application window will remain open until September 1 or until the fund has been depleted. Hence, families are encouraged to apply as soon as they can.

The Department of Health and Social Care (DHSC) has revised concession prices for four products and confirmed three further price concessions for May 2024. This announcement comes in response to representations made by Community Pharmacy England (CPE) on behalf of community pharmacy owners Concession prices have been redetermined for Ezetimibe 10mg tablets, Quetiapine 100mg tablets, Quetiapine 150mg tablets and Quetiapine 200mg tablets. Here are the newly granted concessions: Nicorandil 10mg tablets (60 tablets): £5.05 Nicorandil 20mg tablets (60 tablets): £9.30 Pregabalin 75mg capsules (56 capsules): £1.54 The revised prices will be applicable to prescriptions submitted for payment during the dispensing month of May 2024, and do not apply to June 2024 prescriptions, the CPE noted.

Too many unreasonable demands placed on pharmacists by employers affect their health and wellbeing at work, a stress and wellbeing survey conducted by The Pharmacists' Defence Association (PDA) Union revealed. The survey, conducted during Autumn 2021, covered views of over 2,000 pharmacists employed by big multiples - Lloyds, Boots, and Well. This survey used questions developed by the Health and Safety Executive (HSE), which enabled the union to understand more about stress and wellbeing in three of the largest community pharmacy multiples. Analysing the survey, the PDA said that some pharmacists working for each of the three employers highlighted "unachievable targets, unrealistic time pressures, and most worrying of all reported numerous instances of bullying and harassment." An overwhelming majority of the respondents reflected personal sacrifices made by the pharmacists to ensure patient services are not impacted by the poor conditions and environments in some pharmacies.

As whooping cough cases rise sharply across the UK, the NHS has reactivated the serious shortage protocols (SSPs) for clarithromycin - a commonly prescribed antibiotic to treat this bacterial infection. Pharmacy bodies had recently warned that community pharmacies were struggling to obtain source clarithromycin for patients. Two SSPs, covering clarithromycin 125mg/5mL and 250mg/5mL oral suspensions, were reactivated on 22 May 2024, and extended until 21 June 2024. These protocols state that for every 5mL of clarithromycin 125mg/5mL oral suspension, pharmacy contractors must supply 2.5mL of clarithromycin 250mg/5mL oral suspension; and for every 5mL of clarithromycin 250mg/5mL oral suspension, one clarithromycin 250mg tablet must be supplied. The SSPs apply to cross-border prescriptions, both NHS and private.

Cervical screening is one of the best ways to protect women from cervical cancer, which claims nearly two lives daily in England, according to NHS England. Therefore, all women and those with a cervix between the ages of 25 and 64 are encouraged to attend cervical screening when invited. Sadly, 3 in 10 of those eligible for cervical screening do not take up the potentially life-saving offer, as revealed by the NHS Cervical Screening Programme, England 2022-2023 annual report. Pharmacist Thorrun Govind, also a Healthcare Lawyer (Brabners LLP), underscores the significant role pharmacists and pharmacy teams can play in promoting cervical cancer screening. The former Chair of the Royal Pharmaceutical Society (RPS) in England told Pharmacy Business: "Pharmacists and pharmacy teams are a trusted part of the local community. They therefore have a key part in promoting cervical cancer screening."

To help stop the pharmacists pay delay in Northern Ireland, the Pharmacists' Defence Association (PDA) will present a motion on fairer pay to the ICTU Biennial Delegate Conference, taking place from 5 to 7 July. The PDA motion states, "…there are other employers within the health system, that echo Agenda for Change terms, despite the fact they are essentially private businesses contracted to the NHS, not actually public bodies. While echoing the pay structure has some advantages, these employers also seek to unnecessarily delay pay increases on the basis that the NHS changes are so delayed. The Universities in Ulster Schools of Pharmacy are ranked as some of the highest in the UK. They are gifting our population with high calibre graduates destined to provide excellent patient care. These pharmacists want to stay in a job that helps patients. They want to deliver the care that they have spent years of time and often thousands of pounds to render themselves confident and capable."

The NHS is facing a range of long term challenges which needs to be countered with prevention, enhance personalised care and sustainable performance, health and social care secretary Sajid Javid said on Tuesday (March 8). In his speech on healthcare reform at the Royal College of Physicians in London, he said: "We face some long-term challenges: how to keep the NHS focused on delivery while futureproofing it for changing demographics and disease; how to meet rising patient expectations and address the injustices of widespread disparities; and how to deal with an unsustainable financial trajectory while backing the brilliant people who work in health and care." Javid emphasised on three key points for healthcare reform - prevention, personalisation and performance. He said, prevention is not just about building a 'national hospital service' but a true 'National Health Service'.

All adults aged 50 years and above are eligible for free flu jabs in England under the autumn Covid-19 booster programme, the Department of Health and Social Care (DHSC) has announced. "The flu virus could also be highly infectious at this time of year, so I am also announcing that those eligible for a free flu vaccination this year will include everyone aged 50 and over, primary school children and secondary school pupils in years 7, 8 and 9, as well as people in clinical risk groups, unpaid carers and household contacts of those who are immunosuppressed," said new health secretary Steve Barclay. Commenting on the DHSC's announcement, CCA chief executive Malcolm Harrison said: "We welcome the decision to accept the advice of the JCVI on who can have free Covid-19 boosters and flu jabs this autumn. Community pharmacies have turbo-charged the Covid-19 vaccination programme over the past 18 months and last year we witnessed the most successful community pharmacy flu campaign ever."

The Royal Pharmaceutical Society (RPS) has introduced a new comprehensive learning programme to support pharmacists in Wales to deliver the Pharmacy Independent Prescribing Service (PIPS). Developed in collaboration with Health Education and Improvement Wales (HEIW), the programme is designed to "equip pharmacists with the essential knowledge, skills, and confidence needed to provide excellent patient care." While the primary emphasis is on pharmacists operating within primary care settings, those from various practice settings are also encouraged to register and participate in the programme. Commenting on the collaboration with HEIW, Elen Jones, director for Wales at the Royal Pharmaceutical Society, said that it will empower pharmacists across the country to deliver high-quality prescribing services to local communities.

The Pharmacists' Defence Association (PDA) has raised concerns over "a prominent pharmacist's call to create a sector 'blacklist' for locums regarding disputes over rates." A few contractors took it to the Twitter to share screenshots of the messages by locums demanding more pay, which led to the call for 'blacklisting' those locums. "The motivation regarding the current talk of creating a blacklist seems intrinsically tied to hourly rates. Although there are occasional and isolated anecdotal reports on social media of alleged incidents of locums seeking higher rates than already agreed, these are far outstripped by reports of pharmacy businesses unwilling to negotiate and who do not want to pay the necessary rate to engage a locum and instead have set capped or fixed rates," said the PDA. It added that all parties should honour agreements they enter into, including a pharmacy's commitment to the NHS that it will open at set times to provide pharmaceutical services to patients and the public.

A report released by the Independent Commission has blamed Brexit supply issues for medicine shortages. NHS is forced to pay extortionate prices to fulfil the demand for vital antibiotics, anti-depressants, Attention Deficit Hyperactivity Disorder (ADHD), and Hormone Replacement Therapy (HRT) drugs. The report highlights the impact of affected medicine supply issues on community pharmacies and patients. Janet Morrison, the chief executive of Community Pharmacy England, backed the report and said that the "medicine shortages and market instability appear to be as bad as they have ever been". She also explained how the Ukraine conflict, the COVID-19 pandemic, and broader economic instability also play a major factor in the situation.

Independent charity group, Pharmacist Support has appointed five new trustees to its board - David Downham, Karen Harrowing, Mohammed Hussain, Mala Khiroya, and Alison Scowcroft, for a term of three years. The new recruits will join the existing Board members Anita Cawley, Catherine Harper, Paul Johnson, Steve Lutener, Esther Sadler-Williams, Mark Sweeney and Sarah Willis. Harrowing, Downham and Hussain have begun their 3-year term in January 2022, while Scowcroft and Khiroya would join the board in June. The new appointments are in line with the Charity's plans, announced last year, to enhance its volunteer schemes. "Since the launch of the charity's new strategy in January 2020, the profession has been faced with many new challenges. We are really proud of the work we have done in the last few years to address some of these challenges," said Pharmacist Support chief executive Danielle Hunt.

Two weeks prior to the closing of the hub and spoke consultation, issues around patient safety, costs and competition as well as practicalities such as what to do with uncollected medicines were discussed in a webinar on hub and spoke dispensing on Wednesday (May 26). The webinar was organised by Sigma Pharmaceuticals in association with the National Pharmacy Association (NPA). NPA director of corporate affairs Gareth Jones chaired the event and was joined by Sigma's Hatul Shah and Raj Haria as well as NPA vice chair Nick Kaye and NPA head of advice and support services Jasmine Shah. Kaye said: "There are still many 'unknown unknowns' with hub and spoke and the jury's still out on any potential benefits. I have lots of reservations about cost and it worries me how efficient this is for the business and the long term sustainability for the sector as a whole. Above all we need to think about the patient at the centre of all this and the potential confusion for them." Jasmine Shah felt patient safety was going to be the key in regards to whether the spoke and the hub would hold the ultimate responsibility and "who is going to take the accountability as far as patient care goes". She added: "It is most important that GPhC standards and NHS requirement are both met in identifying all the risks associated with the arrangement with hub and spoke and ensuring that (patient safety) measures are in place. Everything that needs to be looked at is by putting the patient at heart of the arrangement and seeing what is the safest way for them to receive care from both spoke and hub."

Ceuta Group has appointed Michael Yates as chief operating officer (COO). In his new role, he will focus on the exploration of future acquisitions to support the Group's growth plans and ensure it continues to provide innovative services and unlock new opportunities for its clients. Prior to joining Ceuta Group, Yates was associated with Procter & Gamble (P&G) for more than 25 years. His career started in the UK and progressed through senior commercial and managing director roles across Europe, Africa and Asia. During his time at P&G, Yates gained insight and experience in building brands in the UK and globally. He has broad category experience across food & drink as well as health, wellness and personal care, having worked with brands such as Pringles, Sunny Delight, Oral B, Vicks, Head & Shoulders and Pantene. With extensive international experience, Michael brings client-side knowledge and insight of successfully expanding brands and adapting business models for markets across the globe. His appointment bolsters Ceuta Group's leadership structure and will support the Group's growth plans and delivery of superior client service.

The regulatory amendments proposed will enable pharmacists to dispense medicines in their original packaging for private prescriptions starting this Autumn, according to the Department of Health and Social Care. In the recently published draft OPD regulations, the DHSC has indicated that the alterations, permitting pharmacists to vary the dispensed quantity by up to 10 per cent to avoid splitting medicine packs, will be implemented for private prescriptions 'immediately upon the enforcement of the Human Medicines Amendment Regulations in the autumn,' as highlighted in a briefing by Community Pharmacy England. CPE stated that the regulations related to NHS prescriptions will come into effect when the pharmaceutical terms of service regulations expressly apply the OPD amendments. Moreover, new directive mandating the dispensing of sodium valproate products solely in their original packaging (except when an assessment of risk necessitates an alternative approach) will align with the rollout of the private prescription regulations during the autumn. CPE further noted that these regulations are currently in draft, indicating that they are not currently in effect and may undergo revisions prior to their implementation.

The Pharmacists' Defence Association raised concerns over the practice of firing and rehiring employees, which often leads to denial of individuals' rights to redundancy, forcing them to face cuts to their terms and conditions. It noted that some employers may use the 'fire and rehire' practice to force staff to accept lower wages, different hours, or other changes in working conditions. It cited an example of a lawsuit in which Tesco lost a High Court battle when Usdaw won a case to protect workers from unfair tactics. The PDA said although the trade union won the case, the practice of firing and rehiring can still be legal in some circumstances. However, it believes the practice is both immoral and unethical.

John Dawson, the founder and former CEO of Alliance Pharma, has donated £5million to the University of Sunderland towards the creation of a new drug research centre. The donation - the biggest in the university's history - will create the John Dawson Drug Discovery and Development Research Institute to improve health and wellbeing of millions of people worldwide. The new centre has been named after the pharmaceutical entrepreneur and Sunderland graduate who, alongside wife Sam, has provided the funding. He and Sam were on Thursday (April 20) joined by specially invited guests from across the region's health, education, and business communities, to launch the Institute housed in the University's Sciences Complex. Unveiling a plaque inside the building, John said: "It's an absolute honour and privilege to be able to launch the new Drug Discovery and Development Research Institute at the University of Sunderland today. "It's been wonderful to be back on the campus and see the incredible developments that have taken place since I studied pharmacy here more than 50 years ago. "I was immediately impressed at what has been achieved in that intervening half-century and I've been delighted to assist the University continue its development, particularly in the health arena. "I hope the launch of this institute will mark the next phase in the University's evolution and I'm very much looking forward to working with the team as they bring their projects to fruition."

A new report published today (June 29) by the think tank Policy Exchange highlights key role for community pharmacy in management of primary-secondary care interface. The report called Medical Evolution has received cross-party support. It says an equivalent of 15 million GP appointments per year are spent dealing with issues managing care between GP practices and hospitals. Research from the think tank also finds 150,000 people could be on 'hidden' waiting lists (where a patient has been referred by a GP for further treatment, but not included on official hospital waiting lists). On the eve of the NHS Long Term Workforce Plan, the report calls for the development of 'interface specialists' - which could be undertaken by doctors, nurses or community pharmacists to enable them to work more routinely across settings and to strategically plan interface working.

The Professional Pharmacists Association (PDA) has demanded efforts to secure greater support and recognition for community pharmacists from governmental bodies. In its written evidence provided to the Health and Social Care select committee's pharmacy inquiry, the PDA raised concerns about the well-being of pharmacists, specifically for those who belong to minority ethnic groups and race and are subjected to bullying, harassment, and ill-treatment. The association highlighted issues in the workplace that impact pharmacists' health and well-being, including chronic understaffing, sub-standard working environments, an absence of protected training time, and experiences of racism, violence, and abuse. Parallel to the PDA's advocacy, the Royal Pharmaceutical Society (RPS) is intensifying calls for prioritising workforce wellbeing within the pharmacy domain. Stressing the pivotal role of workforce retention in addressing current challenges, RPS emphasises the need for robust support mechanisms and equitable access to mental health services.